Loading...
•
Dec 31, 2022
Quantum-Si Q4 2022 Earnings Report
Quantum-Si reported financial results for Q4 2022, highlighted by the launch of Platinum and strategic partnerships.
Key Takeaways
Quantum-Si Incorporated reported a net loss of $33.14 million for the fourth quarter of 2022. The company launched Platinum, its benchtop protein sequencer, and executed multiple industry collaborations. They expect cash runway into 2026.
Launched Platinum, the world’s first next-generation single-molecule protein sequencing system, in December 2022.
Hired Grace Johnston, Ph.D. as Chief Commercial Officer and added key sales and market development personnel.
Partnered with Aviva Systems Biology to co-develop sample preparation kits for protein sequencing research workflows with Platinum.
Announced a partnership and license agreement with Biovista to integrate Biovista’s database and visualization technology into Quantum-Si’s Cloud analytics.
Forward Guidance
Quantum-Si plans to begin beta testing for CarbonTM in Q2 2023 and expects non-GAAP operating expenses to be approximately flat in 2023.
Positive Outlook
- Begin beta testing for CarbonTM in Q2 2023.
- Launch CarbonTM in the second half of the year.
- Committed to preserving financial strength.
- Continue investments in R&D and commercialization.
- Expects non-GAAP operating expenses to be approximately flat in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...